Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ceftobiprole vs standard-of-care cephalosporin ± vancomycin in paediatric hospital- or community-acquired pneumonia
2013-004615-45Phase 3Completed
- Sponsor
- Basilea Pharmaceutica
- Start
- Oct 2016
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial in hospital-acquired pneumonia (HAP) and community-acquired pneumonia (CAP) comparing Ceftobiprole with Standard-of-care cephalosporin ± vancomycin (2 arms). Primary endpoint: Safety (adverse events). Started Oct 2016; status: completed.
02
Drugs
ceftobiprole medocaril
03
Conditions
hospital-acquired pneumonia (HAP)community-acquired pneumonia (CAP)
Beyond the preview
Go deeper on 2013-004615-45.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-004615-45.